• Perma-Fix Reports 17% Increase In Revenue to $18.5 Million for the Third Quarter of 2022

    المصدر: Nasdaq GlobeNewswire / 03 نوفمبر 2022 08:00:03   America/New_York

    ATLANTA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the third quarter ended September 30, 2022.

    Mark Duff, President and CEO of the Company, commented, “I am pleased to report that we achieved a 17% increase in revenue to $18.5 million and a 38% increase in gross profit for the third quarter of 2022, compared to the same period last year. As previously announced, we were able to reach full operational status on several projects that had been delayed due, in part, to the impact of COVID-19 pandemic, contributing to revenue growth within our Service Segment in the third quarter of 2022. While federal government clients remain slow to procure new task orders, we realized an increase in procurements in September 2022, which we believe will continue in the fourth quarter of 2022. Moreover, we are encouraged by our bidding pipeline, with many of these contracts expected to be awarded over the next few quarters.”

    “Within our Treatment Segment, we benefitted from a 46% increase in waste receipts to $9.1 million as compared to $6.2 million for same quarter last year, including both commercial and international waste. Excluding the one-time significant request for equitable adjustment (“REA”) under a government waste generator contract in the third quarter of 2021, our Treatment Segment revenue would have increased by approximately $1.3 million or 17% in the third quarter of 2022. We achieved these results despite the negative impact of delays in waste shipments from certain customers at our Florida facility due, in part, to Hurricane Ian. At the same time, we continue to expand our waste treatment offering to the commercial utility sector, along with the oil and gas markets, which we believe will likely be sustainable for several years. We have defined new procurement and market expansion opportunities with the US Navy, the US Department of Defense (DOD) and the US Department of Energy (DOE). The second phase of the Test Bed Initiative (TBI) project continues to move forward as DOE intends to submit the Research, Development and Demonstration (RD&D) permit to the state by the end of first quarter of 2023. We expect this will trigger review and approval by the State of Washington to support the shipment of 2,000 gallons of this waste shortly after approval.”

    “Overall, we continue to see improvement in waste receipts. In addition, qualifying for the Employee Retention Credit (“ERC”) helped with offsetting some of the losses incurred from the pandemic. We believe our foundation, coupled with expansion of our treatment capabilities, increased bidding opportunities and improved federal budgets will continue to support our growth objectives.”

    Financial Results
    Revenue for the third quarter of 2022 was $18.5 million versus $15.8 million for the same period last year. Revenue for the Services Segment increased to approximately $9.6 million for the three months ended September 30, 2022 from $6.9 million for the corresponding period of 2021 due to achievement of full operational status on certain projects which had previously been delayed/curtailed due to COVID-19 impact and/or administrative delays experienced by certain customers since the award of these project to us late in the second quarter of 2021. Revenue for the Treatment Segment was approximately $8.9 million for each of the third quarters of 2022 and 2021. Revenue for our Treatment Segment for the third quarter of 2021 included approximately $1.3 million recognized from a significant request for equitable adjustment (“REA”) under a government waste generator contract resulting from certain pricing provisions of the contract. Excluding this REA, Treatment Segment revenue increased approximately $1.3 million primarily due to higher waste volume which was offset by lower averaged price waste due to revenue mix. Our Treatment Segment continues to see steady improvement in waste receipts since the second quarter of 2022 from certain customers who had previously delayed waste shipments.

    Gross profit for the third quarter of 2022 was $3.1 million versus $2.2 million for the third quarter of 2021. Excluding the REA recorded in the third quarter of 2021 within our Treatment Segment as discussed above, gross profit increased in both segments where Treatment Segment gross profit increase by approximately $766,000 primarily due to higher waste volume which was partially offset by lowered averaged price waste from revenue mix and Services Segment gross profit increased by approximately $1.4 million due to higher revenue from increased work.

    Operating loss for the third quarter of 2022 was approximately $928,000 versus operating loss of $1.4 million for the third quarter of 2021. Net income attributable to common stockholders for the third quarter of 2022 was approximately $664,000 or $0.05 per share (both basic and diluted) versus $1.4 million or $0.11 per share for the third quarter of 2021. Net income attributable to common stockholders for the third quarter of 2022 included an income recorded in the amount of approximately $2.0 million (within other income and current other receivables), representing a refundable tax credit against the Company’s shares of certain payroll taxes as permitted by the ERC program under the Coronavirus Aid, Relief and Economic Securities Act (“CARES Act”), as amended. The ERC program is provided to qualifying businesses that kept employee on their payroll during the COVID-19 pandemic. Net income attributable to common stockholders for the third quarter of 2021 included a tax benefit recorded in the amount of approximately $2.4 million resulting from the release of valuation allowance on the Company’s deferred tax assets.

    The Company recorded Adjusted EBITDA of ($374,000) from continuing operations during the quarter ended September 30, 2022, as compared to Adjusted EBITDA of ($798,000) for the same period of 2021. The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before research and development (“R&D”) costs related to the Medical Isotope project, gain on extinguishment of debt and income from ERC refund claim (net of costs incurred). As previously disclosed, in December 2021, the Company made the strategic decision to cease all R&D activities under the Medical Segment and sold 100% of its interest in Perma-Fix Medical S.A., which comprised its Medical Segment. Both EBITDA and Adjusted EBITDA are not measures of performance calculated in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”), and should not be considered in isolation of, or as a substitute for, earnings as an indicator of operating performance or cash flows from operating activities as a measure of liquidity. The Company believes the presentation of EBITDA and Adjusted EBITDA is relevant and useful by enhancing the readers’ ability to understand the Company’s operating performance. The Company’s management utilizes EBITDA and Adjusted EBITDA as a means to measure performance. The Company’s measurements of EBITDA and Adjusted EBITDA may not be comparable to similar titled measures reported by other companies. The table below reconciles EBITDA and Adjusted EBITDA, both non-GAAP measures, to GAAP numbers for income (loss) from continuing operations for the three and nine months ended September 30, 2022 and 2021.

      (Unaudited) (Unaudited)
      Three Months Ended Nine Months Ended
      September 30, September 30,
    (In thousands)  2022   2021   2022   2021 
    Income (loss) from continuing operations $824  $1,381  $(1,682) $3,464 
             
             
    Adjustments:        
    Depreciation & amortization  497   409   1,433   1,208 
    Interest income  (29)  (2)  (69)  (23)
    Interest expense  47   77   123   209 
    Interest expense - financing fees  16   11   44   28 
    Income tax benefit (benefit)  179   (2,836)  (147)  (2,840)
             
    EBITDA  1,534   (960)  (298)  2,046 
             
    Income from ERC refund claim, net(1)  (1,908)     (1,908)   
    R&D costs related to Medical Isotope project     162      311 
    Gain on extinguishment of debt           (5,381)
             
    Adjusted EBITDA $(374) $(798) $(2,206) $(3,024)
             
    (1) net of costs incurred in connection with the ERC program in the amount of approximately $67.
     

    The tables below present certain unaudited financial information for the business segments, which excludes allocation of corporate expenses. As noted above, in December 2021, the Company made the strategic decision to cease all R&D activities under the Medical Segment and sold 100% of its interest in Perma-Fix Medical S.A., which comprised of its Medical Segment.

      Three Months Ended Nine Months Ended
      September 30, 2022 September 30, 2022
      (Unaudited) (Unaudited)
    (In thousands) Treatment Services Treatment Services
    Net revenues $8,877  $9,595  $24,749  $29,093 
    Gross profit  1,967   1,103   4,168   3,422 
    Segment profit  1,628   710   1,766   1,580 


      Three Months Ended Nine Months Ended
      September 30, 2021 September 30, 2021
        (Unaudited)   (Unaudited)
    (In thousands) Treatment Services Medical Treatment Services Medical
    Net revenues $8,893  $6,904  $  $24,094  $30,981  $ 
    Gross profit (negative gross profit)  2,487   (263)     4,845   701    
    Segment profit (loss)  1,316   (984)  (162)  1,682   (1,731)  (311)
                   

    COVID-19

    The Company continues to proactively update its ongoing business operations and safety plans, which we believe will mitigate any potential impact of COVID-19. However, as the situations surrounding COVID-19 remain fluid, the full impact and extent of the pandemic on the Company’s financial results cannot be estimated with any degree of certainty.

    Conference Call

    Perma-Fix will host a conference call at 11:00 a.m. ET on Thursday, November 3, 2022. The call will be available on the Company’s website at https://ir.perma-fix.com/conference-calls, or by calling 877-545-0523 for U.S. callers or +1 973-528-0016 for international callers, and by entering access code: 996909. The conference call will be led by Mark J. Duff, Chief Executive Officer, Dr. Louis F. Centofanti, Executive Vice President of Strategic Initiatives, and Ben Naccarato, Executive Vice President and Chief Financial Officer of Perma-Fix Environmental Services, Inc.

    A webcast will also be archived on the Company’s website and a telephone replay of the call will be available approximately one hour following the call, through Thursday, November 10, 2022 and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code: 47036.

    About Perma-Fix Environmental Services
    Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the DOE, the DOD, and the commercial nuclear industry. The Company’s nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities, nationwide.

    Please visit us at http://www.perma-fix.com.

    This press release contains “forward-looking statements” which are based largely on the Company's expectations and are subject to various business risks and uncertainties, certain of which are beyond the Company's control. Forward-looking statements generally are identifiable by use of the words such as “believe”, “expects”, “intends”, “anticipate”, “plans to”, “estimates”, “projects”, and similar expressions. Forward-looking statements include, but are not limited to: increase in orders and procurements; award of contracts the next few quarters; expansion of waste treatment offering; submission of RD&D permit by the DOE; approval by State of Washington to support shipment of the next 2,000 gallons waste; and growth objectives. These forward-looking statements are intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. While the Company believes the expectations reflected in this news release are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors which could cause future outcomes to differ materially from those described in this release, including, without limitation, future economic conditions; industry conditions; competitive pressures; our ability to apply and market our new technologies; the government or such other party to a contract granted to us fails to abide by or comply with the contract or to deliver waste as anticipated under the contract; inability to win bid projects; failure of Congress to provides continuing funding for the DOD’s and DOE’s remediation projects; ability to obtain new foreign and domestic remediation contracts; inability to meet financial covenants; impact of COVID-19; and the “Risk Factors” discussed in, and the additional factors referred to under "Special Note Regarding Forward-Looking Statements" of, our 2021 Form 10-K and Form 10-Q for quarters ended March 31, 2022, June 30, 2022 and September 30, 2022. The Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that bear upon forward-looking statements.

    FINANCIAL TABLES FOLLOW

    Contacts:
    David K. Waldman-US Investor Relations
    Crescendo Communications, LLC
    (212) 671-1021

    Herbert Strauss-European Investor Relations
    herbert@eu-ir.com
    +43 316 296 316




    PERMA-FIX ENVIRONMENTAL SERVICES, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS
    (UNAUDITED)

      Three Months Ended Nine Months Ended
      September 30, September 30,
    (Amounts in Thousands, Except for Per Share Amounts) 2022 2021 2022 2021
                 
    Net revenues $18,472  $15,797  $53,842  $55,075 
    Cost of goods sold 15,402  13,573  46,252  49,529 
    Gross profit 3,070  2,224  7,590  5,546 
                 
    Selling, general and administrative expenses 3,929  3,348  11,035  9,550 
    Research and development 69  243  245  538 
    Loss on disposal of property and equipment   1  1  1 
    Loss from operations (928) (1,368) (3,691) (4,543)
                 
    Other income (expense):            
    Interest income 29  2  69  23 
    Interest expense (47) (77) (123) (209)
    Interest expense-financing fees (16) (11) (44) (28)
    Other 1,965  (1) 1,960   
    Gain on extinguishment of debt       5,381 
    Income (loss) from continuing operations before taxes 1,003  (1,455) (1,829) 624 
    Income tax expense (benefit) 179  (2,836) (147) (2,840)
    Income (loss) from continuing operations, net of taxes 824  1,381  (1,682) 3,464 
                 
    Loss from discontinued operations, net of taxes (160) (43) (442) (285)
    Net income (loss) 664  1,338  (2,124) 3,179 
                 
    Net loss attributable to non-controlling interest   (64)   (123)
                 
    Net income (loss) attributable to Perma-Fix Environmental            
    Services, Inc. common stockholders $664  $1,402  $(2,124) $3,302 
                 
    Net income (loss) per common share attributable to Perma-Fix            
    Environmental Services, Inc. stockholders - basic:            
    Continuing operations $.06  $.12  $(.13) $.29 
    Discontinued operations  (.01) (.01) (.03) (.02)
    Net income (loss) per common share $.05  $.11  $(.16) $.27 
                 
    Net income (loss) per common share attributable to Perma-Fix            
    Environmental Services, Inc. stockholders - diluted:            
    Continuing operations $.06  $.12  $(.13) $.29 
    Discontinued operations (.01) (.01) (.03) (.02)
    Net income (loss) per common share $.05  $.11  $(.16) $.27 
                 
    Number of common shares used in computing            
    net income (loss) per share:            
    Basic 13,297  12,198  13,265  12,181 
    Diluted 13,447  12,406  13,265  12,416 


    PERMA-FIX ENVIRONMENTAL SERVICES, INC.
    CONSOLIDATED BALANCE SHEET

      September 30, December 31,
       2022   2021 
    (Amounts in Thousands, Except for Share and Per Share Amounts) (Unaudited) (Audited)
         
    ASSETS    
    Current assets:    
    Cash $1,858  $4,440 
    Account receivable, net of allowance for doubtful    
    accounts of $31 and $85, respectively 9,993   11,372 
    Unbilled receivables  6,306   8,995 
    Other current assets  7,266   5,152 
    Assets of discontinued operations included in current assets  17   15 
    Total current assets  25,440   29,974 
         
    Net property and equipment  19,515   18,609 
    Property and equipment of discontinued operations  81   81 
         
    Operating lease right-of-use assets  2,087   2,460 
         
    Intangibles and other assets  26,066   26,177 
    Total assets $73,189  $77,301 
         
    LIABILITIES AND STOCKHOLDERS' EQUITY    
    Current liabilities $23,008  $25,408 
    Current liabilities related to discontinued operations  927   506 
    Total current liabilities  23,935   25,914 
         
    Long-term liabilities  10,017   10,126 
    Long-term liabilities related to discontinued operations  267   677 
    Total liabilities  34,219   36,717 
    Commitments and Contingencies    
    Stockholders' equity:    
    Preferred Stock, $.001 par value; 2,000,000 shares authorized,    
    no shares issued and outstanding      
    Common Stock, $.001 par value; 30,000,000 shares authorized,    
    13,305,750 and 13,222,552 shares issued, respectively;    
    13,298,108 and 13,214,910 shares outstanding, respectively  13   13 
    Additional paid-in capital  114,993   114,307 
    Accumulated deficit  (75,744)  (73,620)
    Accumulated other comprehensive loss  (204)  (28)
    Less Common Stock held in treasury, at cost: 7,642 shares  (88)  (88)
    Total stockholders' equity  38,970   40,584 
         
    Total liabilities and stockholders' equity $73,189  $77,301 
         


    Primary Logo

شارك على،